- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07645066
Posterosuperior Bundle Pacing for Prevention of Atrial Fibrillation in Patients With Sinus Node Dysfunction (PSB-AF)
A Prospective, Multicenter, Randomized Controlled Trial Evaluating the Effect of Posterosuperior Bundle Pacing on Atrial Fibrillation Prevention in Patients With Sinus Node Dysfunction
This study aims to evaluate whether posterosuperior bundle (PSB) pacing reduces the incidence of atrial fibrillation (AF) in patients with sinus node dysfunction (SND) undergoing pacemaker implantation. Approximately 300 patients will be enrolled and randomized to receive atrial pacing at either the PSB region or the right atrial appendage (RAA). The primary endpoint is the occurrence of AF episodes lasting ≥6 minutes, as detected by device or surface electrocardiogram. Patients will be followed for up to 24 months.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Sinus node dysfunction (SND) is a common indication for permanent pacemaker implantation. Conventional right atrial appendage (RAA) pacing may result in delayed or dyssynchronous atrial activation, potentially increasing the risk of atrial arrhythmias. Posterosuperior bundle (PSB) pacing is a novel physiological atrial pacing approach. This study is a prospective, multicenter, open-label, randomized controlled trial. A total of approximately 300 eligible SND patients indicated for pacemaker implantation will be enrolled and randomly assigned (1:1) to PSB pacing or RAA pacing. Ventricular pacing will be performed using left bundle branch area pacing in both groups. Following implantation, the pacemaker will be programmed in DDD mode with a lower rate of 70 beats/min during daytime and 60 beats/min during nighttime. Rate-responsive pacing will be enabled by default when available; ATP will be disabled by default. Participants will be followed at 3, 6, 12, and 24 months after implantation. The primary endpoint is the occurrence of AF episodes lasting ≥6 minutes. Secondary endpoints include atrial high-rate episodes, AF burden, pacing parameters, ECG and echocardiographic indices, laboratory findings, and mortality outcomes. Safety endpoints include procedural complications and device-related adverse events.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Zhaohui Qiu
- Telefonnummer: +862152039999
- E-Mail: qzh3503@shtrhospital.com
Studienorte
-
-
Anhui
-
Anqing, Anhui, China
- Noch keine Rekrutierung
- China Medical University affiliated AnQing Municipal Hospital
-
Kontakt:
- Liangchuan Chen
- Telefonnummer: +86 13956556381
- E-Mail: aqslyy@163.com
-
Tongling, Anhui, China
- Noch keine Rekrutierung
- Tongling People's Hospital
-
Kontakt:
- Ying Zhang
- Telefonnummer: +86 18005669636
- E-Mail: tlph@mail.wh.ah.cn
-
-
Guizhou
-
Zunyi, Guizhou, China
- Noch keine Rekrutierung
- Affiliated Hospital of Zunyi Medical College
-
Kontakt:
- Xianping Long
- Telefonnummer: +86 13885294999
- E-Mail: longxianping1201@163.com
-
-
Hubei
-
Wuhan, Hubei, China
- Noch keine Rekrutierung
- Wuhan Asia General Hospital
-
Kontakt:
- Hongwei Han
- Telefonnummer: +86 15327298622
- E-Mail: wuhanagh@163.com
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200336
- Rekrutierung
- Tong Ren Hospital, Shanghai Jiaotong University School of Medicine
-
Kontakt:
- Zhaohui Qiu
- Telefonnummer: +862152039999
- E-Mail: qzh3503@shtrhospital.com
-
Shanghai, Shanghai Municipality, China
- Noch keine Rekrutierung
- Fudan University affiliated Huadong Hospital
-
Kontakt:
- Zhengqi Kong
- Telefonnummer: +86 13816620347
- E-Mail: huadongtexu@163.com
-
Shanghai, Shanghai Municipality, China
- Noch keine Rekrutierung
- Shanghai Jiaotong University affiliated Shanghai Ninth People's Hospital
-
Kontakt:
- Zongqi Zhang
- Telefonnummer: +86 18049827281
- E-Mail: zqzhang_scdc@126.com
-
Shanghai, Shanghai Municipality, China
- Noch keine Rekrutierung
- Shanghai Jiaotong University affiliated Shanghai Sixth People's Hospital
-
Kontakt:
- Yisheng Pan
- Telefonnummer: +86 13817273883
- E-Mail: shlygjyl@163.com
-
Shanghai, Shanghai Municipality, China
- Noch keine Rekrutierung
- Shanghai University of Traditional Chinese Medicine affiliated Putuo Hospital
-
Kontakt:
- Zongjun Liu
- Telefonnummer: +86 19821577439
- E-Mail: lzj72@126.com
-
Shanghai, Shanghai Municipality, China
- Noch keine Rekrutierung
- Tongji University School of Medicine affiliated Tongji University
-
Kontakt:
- Bing Sun
- Telefonnummer: +86 13918324334
- E-Mail: woowoocncn@163.com
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Age ≥18 years
- Indication for permanent pacemaker implantation, including:
- Sinus node dysfunction, defined as at least one of the following:
- Symptomatic sinus bradycardia
- Tachy-brady syndrome
- Chronotropic incompetence
- Sinus pause / arrest
- Atrioventricular block (if present); if ventricular pacing is required, left bundle branch area pacing is planned
- Expected survival >1 year
- Panned implantation of a device capable of detecting atrial high-rate episodes
- Willing and able to provide informed consent
Exclusion Criteria:
- Persistent atrial fibrillation (AF) (>7 days), long-standing persistent AF, permanent AF, or prior atrioventricular node ablation
- Prior cardiac implantable electronic device (CIED) requiring replacement, upgrade, or revision
- Indication for cardioverter-defibrillator (ICD) or cardiac resynchronization therapy (CRT-D)
- Prior cardiac surgery, severe hepatic or renal dysfunction, or other life-threatening systemic diseases
- Acute myocardial infarction within 3 months before enrollment
- Persistent left superior vena cava or dextrocardia
- Pregnant or breastfeeding women, or women of childbearing potential not using effective contraception
- Participation in another clinical trial that may interfere
- Any condition that, in the opinion of the investigator, makes participation unsuitable
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: PSB pacing
Patients were randomly assigned to receive posterosuperior bundle pacing for atrial pacing during regular pacemaker implantation procedures. |
Atrial pacing lead implanted at the posterosuperior bundle region. Left bundle branch area pacing will be applied if ventricular pacing is necessary. |
|
Aktiver Komparator: RAA pacing
Patients were randomly assigned to receive right atrial appendage pacing for atrial pacing during regular pacemaker implantation procedures. |
Atrial pacing lead implanted at the right atrial appendage. Left bundle branch area pacing will be applied if ventricular pacing is necessary. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence of atrial fibrillation
Zeitfenster: From implantation to regular follow-ups up to 24 months
|
Incidence of atrial fibrillation ≥ 6 minutes during follow-ups |
From implantation to regular follow-ups up to 24 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Atrial high-rate episodes
Zeitfenster: From implantation to regular follow-ups up to 24 months
|
From implantation to regular follow-ups up to 24 months
|
|
|
AF burden
Zeitfenster: From implantation to regular follow-ups up to 24 months
|
From implantation to regular follow-ups up to 24 months
|
|
|
eGFR
Zeitfenster: At baseline, before discharge, and 6 - month follow-up
|
At baseline, before discharge, and 6 - month follow-up
|
|
|
All-cause mortality
Zeitfenster: From implantation to regular follow-ups up to 24 months
|
From implantation to regular follow-ups up to 24 months
|
|
|
Cardiovascular death
Zeitfenster: From implantation to regular follow-ups up to 24 months
|
From implantation to regular follow-ups up to 24 months
|
|
|
Intrinsic P-wave duration
Zeitfenster: At baseline and regular follow-ups up to 24 months, when intrinsic atrial rhythm is assessable
|
Measured from the onset of the P wave to the end |
At baseline and regular follow-ups up to 24 months, when intrinsic atrial rhythm is assessable
|
|
Paced P-wave duration
Zeitfenster: From implantation to regular follow-ups up to 24 months
|
Measured from the pacing stimulus to P wave end duration |
From implantation to regular follow-ups up to 24 months
|
|
Left ventricular ejection fraction (LVEF)
Zeitfenster: At baseline, 6-, 12-, and 24-month follow-ups
|
Standard transthoracic echocardiographic parameter |
At baseline, 6-, 12-, and 24-month follow-ups
|
|
Left atrial diameter (LAD)
Zeitfenster: At baseline, 6-, 12-, and 24-month follow-ups
|
Standard transthoracic echocardiographic parameter |
At baseline, 6-, 12-, and 24-month follow-ups
|
|
Right atrial diameter (RAD)
Zeitfenster: At baseline, 6-, 12-, and 24-month follow-ups
|
Standard transthoracic echocardiographic parameter |
At baseline, 6-, 12-, and 24-month follow-ups
|
|
Left ventricular end-systolic diameter (LVESD)
Zeitfenster: At baseline, 6-, 12-, and 24-month follow-ups
|
Standard transthoracic echocardiographic parameter |
At baseline, 6-, 12-, and 24-month follow-ups
|
|
Left ventricular end-diastolic diameter (LVEDD)
Zeitfenster: At baseline, 6-, 12-, and 24-month follow-ups
|
Standard transthoracic echocardiographic parameter |
At baseline, 6-, 12-, and 24-month follow-ups
|
|
E/e'
Zeitfenster: At baseline, 6-, 12- , 24-month follow-ups
|
Standard transthoracic echocardiographic parameter |
At baseline, 6-, 12- , 24-month follow-ups
|
|
Mitral regurgitation severity
Zeitfenster: At baseline, 6-, 12- , 24-month follow ups
|
Standard transthoracic echocardiographic measurement using standard semi-quantitative grading (none/trace, mild, moderate, or severe) |
At baseline, 6-, 12- , 24-month follow ups
|
|
Tricuspid regurgitation severity
Zeitfenster: At baseline, 6-, 12-, 24- month follow-ups
|
Standard transthoracic echocardiographic measurement using standard semi-quantitative grading (none/trace, mild, moderate, or severe) |
At baseline, 6-, 12-, 24- month follow-ups
|
|
NT-pro BNP
Zeitfenster: At baseline, before discharge, and 6-month follow-up
|
Standard transthoracic echocardiographic parameter |
At baseline, before discharge, and 6-month follow-up
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Atrial pacing capture threshold
Zeitfenster: From implantation to regular follow-ups up to 24 months
|
From implantation to regular follow-ups up to 24 months
|
|
|
Atrial sensing amplitude
Zeitfenster: From implantation to regular follow-ups up to 24 months
|
From implantation to regular follow-ups up to 24 months
|
|
|
Atrial pacing output
Zeitfenster: From implantation to regular follow-ups up to 24 months
|
From implantation to regular follow-ups up to 24 months
|
|
|
Procedural complications
Zeitfenster: Perioperative
|
Safety Outcome |
Perioperative
|
|
Postoperative adverse events
Zeitfenster: From implantation to regular follow-ups up to 24 months
|
Safety Outcome, including lead-related complications, thromboembolic events, etc. |
From implantation to regular follow-ups up to 24 months
|
|
Paced P-wave morphology
Zeitfenster: From implantation to regular follow-ups up to 24 months
|
positive, negative, notched, and biphasic |
From implantation to regular follow-ups up to 24 months
|
|
Intrinsic P-wave morphology
Zeitfenster: At baseline, implant, and regular follow-ups up to 24 months when intrinsic atrial rhythm is assessable
|
positive, negative, notched, and biphasic |
At baseline, implant, and regular follow-ups up to 24 months when intrinsic atrial rhythm is assessable
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
- PSB-AF
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .